A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic
Abstract Background Hydroxyurea is one of the earliest drugs that showed promise in the management of haemoglobinopathies that include β-thalassaemia and sickle cell disease. Despite this, many aspects of hydroxyurea are either unknown or understudied; specifically, its usefulness in β-thalassaemia...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-03-01
|
| Series: | Orphanet Journal of Rare Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13023-021-01757-w |
| _version_ | 1819141529282805760 |
|---|---|
| author | Nirmani Yasara Anuja Premawardhena Sachith Mettananda |
| author_facet | Nirmani Yasara Anuja Premawardhena Sachith Mettananda |
| author_sort | Nirmani Yasara |
| collection | DOAJ |
| description | Abstract Background Hydroxyurea is one of the earliest drugs that showed promise in the management of haemoglobinopathies that include β-thalassaemia and sickle cell disease. Despite this, many aspects of hydroxyurea are either unknown or understudied; specifically, its usefulness in β-thalassaemia major and haemoglobin E β-thalassaemia is unclear. However, during COVID-19 pandemic, it has become a valuable adjunct to transfusion therapy in patients with β-haemoglobinopathies. In this review, we aim to explore the available in vitro and in vivo mechanistic data and the clinical utility of hydroxyurea in β-haemoglobinopathies with a special emphasis on its usefulness during the COVID-19 pandemic. Main body Hydroxyurea is an S-phase-specific drug that reversibly inhibits ribonucleoside diphosphate reductase enzyme which catalyses an essential step in the DNA biosynthesis. In human erythroid cells, it induces the expression of γ-globin, a fetal globin gene that is suppressed after birth. Through several molecular pathways described in this review, hydroxyurea exerts many favourable effects on the haemoglobin content, red blood cell indices, ineffective erythropoiesis, and blood rheology in patients with β-haemoglobinopathies. Currently, it is recommended for sickle cell disease and non-transfusion dependent β-thalassaemia. A number of clinical trials are ongoing to evaluate its usefulness in transfusion dependent β-thalassaemia. During the COVID-19 pandemic, it was widely used as an adjunct to transfusion therapy due to limitations in the availability of blood and logistical disturbances. Thus, it has become clear that hydroxyurea could play a remarkable role in reducing transfusion requirements of patients with haemoglobinopathies, especially when donor blood is a limited resource. Conclusion Hydroxyurea is a well-tolerated oral drug which has been in use for many decades. Through its actions of reversible inhibition of ribonucleoside diphosphate reductase enzyme and fetal haemoglobin induction, it exerts many favourable effects on patients with β-haemoglobinopathies. It is currently approved for the treatment of sickle cell disease and non-transfusion dependent β-thalassaemia. Also, there are various observations to suggest that hydroxyurea is an important adjunct in the treatment of transfusion dependent β-thalassaemia which should be confirmed by randomised clinical trials. |
| first_indexed | 2024-12-22T11:55:54Z |
| format | Article |
| id | doaj.art-c561ef68190d41c2b939ad2e9a3d7366 |
| institution | Directory Open Access Journal |
| issn | 1750-1172 |
| language | English |
| last_indexed | 2024-12-22T11:55:54Z |
| publishDate | 2021-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Orphanet Journal of Rare Diseases |
| spelling | doaj.art-c561ef68190d41c2b939ad2e9a3d73662022-12-21T18:26:48ZengBMCOrphanet Journal of Rare Diseases1750-11722021-03-0116111210.1186/s13023-021-01757-wA comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemicNirmani Yasara0Anuja Premawardhena1Sachith Mettananda2Department of Paediatrics, Faculty of Medicine, University of KelaniyaDepartment of Medicine, Faculty of Medicine, University of KelaniyaDepartment of Paediatrics, Faculty of Medicine, University of KelaniyaAbstract Background Hydroxyurea is one of the earliest drugs that showed promise in the management of haemoglobinopathies that include β-thalassaemia and sickle cell disease. Despite this, many aspects of hydroxyurea are either unknown or understudied; specifically, its usefulness in β-thalassaemia major and haemoglobin E β-thalassaemia is unclear. However, during COVID-19 pandemic, it has become a valuable adjunct to transfusion therapy in patients with β-haemoglobinopathies. In this review, we aim to explore the available in vitro and in vivo mechanistic data and the clinical utility of hydroxyurea in β-haemoglobinopathies with a special emphasis on its usefulness during the COVID-19 pandemic. Main body Hydroxyurea is an S-phase-specific drug that reversibly inhibits ribonucleoside diphosphate reductase enzyme which catalyses an essential step in the DNA biosynthesis. In human erythroid cells, it induces the expression of γ-globin, a fetal globin gene that is suppressed after birth. Through several molecular pathways described in this review, hydroxyurea exerts many favourable effects on the haemoglobin content, red blood cell indices, ineffective erythropoiesis, and blood rheology in patients with β-haemoglobinopathies. Currently, it is recommended for sickle cell disease and non-transfusion dependent β-thalassaemia. A number of clinical trials are ongoing to evaluate its usefulness in transfusion dependent β-thalassaemia. During the COVID-19 pandemic, it was widely used as an adjunct to transfusion therapy due to limitations in the availability of blood and logistical disturbances. Thus, it has become clear that hydroxyurea could play a remarkable role in reducing transfusion requirements of patients with haemoglobinopathies, especially when donor blood is a limited resource. Conclusion Hydroxyurea is a well-tolerated oral drug which has been in use for many decades. Through its actions of reversible inhibition of ribonucleoside diphosphate reductase enzyme and fetal haemoglobin induction, it exerts many favourable effects on patients with β-haemoglobinopathies. It is currently approved for the treatment of sickle cell disease and non-transfusion dependent β-thalassaemia. Also, there are various observations to suggest that hydroxyurea is an important adjunct in the treatment of transfusion dependent β-thalassaemia which should be confirmed by randomised clinical trials.https://doi.org/10.1186/s13023-021-01757-wHydroxyureaThalassaemiaSickle cell diseaseHaemoglobinopathiesγ-Globin inductionBlood transfusion |
| spellingShingle | Nirmani Yasara Anuja Premawardhena Sachith Mettananda A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic Orphanet Journal of Rare Diseases Hydroxyurea Thalassaemia Sickle cell disease Haemoglobinopathies γ-Globin induction Blood transfusion |
| title | A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic |
| title_full | A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic |
| title_fullStr | A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic |
| title_full_unstemmed | A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic |
| title_short | A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic |
| title_sort | comprehensive review of hydroxyurea for β haemoglobinopathies the role revisited during covid 19 pandemic |
| topic | Hydroxyurea Thalassaemia Sickle cell disease Haemoglobinopathies γ-Globin induction Blood transfusion |
| url | https://doi.org/10.1186/s13023-021-01757-w |
| work_keys_str_mv | AT nirmaniyasara acomprehensivereviewofhydroxyureaforbhaemoglobinopathiestherolerevisitedduringcovid19pandemic AT anujapremawardhena acomprehensivereviewofhydroxyureaforbhaemoglobinopathiestherolerevisitedduringcovid19pandemic AT sachithmettananda acomprehensivereviewofhydroxyureaforbhaemoglobinopathiestherolerevisitedduringcovid19pandemic AT nirmaniyasara comprehensivereviewofhydroxyureaforbhaemoglobinopathiestherolerevisitedduringcovid19pandemic AT anujapremawardhena comprehensivereviewofhydroxyureaforbhaemoglobinopathiestherolerevisitedduringcovid19pandemic AT sachithmettananda comprehensivereviewofhydroxyureaforbhaemoglobinopathiestherolerevisitedduringcovid19pandemic |